Free Papers

Does the systems of anterior chamber stabilization and IOP control can decrease endothelial cells loss during cataract phacoemulsification?

Free Paper Details

First Author: V.Shevchyk UKRAINE

Co Author(s):    O. Chugai                    

Abstract Details

Purpose:

To assess the opportunity of modern systems of anterior chamber stabilization and IOP control to preserved endothelial cells during standard cataract phacoemulsification.

Setting:

LLD “Shevchyk Vasyl eye microsurgery”, Chernihiv, Ukraine.

Methods:

Our study include 200 patients (cataract grade 2-3) that was divided into two groups: control and study. In control group (randomly selected 100 patients) to undergo phacoemulsification on Stellaris System, in second (study group) - on Stellaris Elite System (with IOP and anterior chamber stability control). All surgeries were performed during 1 month by one surgeon using the same technique, viscoelastics and instruments. The count of endothelial cells in central area just before surgery and after 30 days were done, using specular microscope SP-1P (Topcon).

Results:

Before surgery the counts of endothelial cells in both groups were similar - 2430±260 and 2390±233 cells/mm2, between-group differences – P= 0.97). On the first postoperation day, a clear, transparent cornea in study group and slight oedema in control group was noticed, that was confirmed by better visual acuity of patients in study group. After 1 month, a loss of endothelial cells in both groups were noticed, but in the control group it was 13.6±6.6%, and in the study - only 3.8±3.6%, between-group differences – P= 0.005.

Conclusions:

The implementation of phacoemulsification devices with IOP and anterior chamber stability control in routine practice allows us to preserve endothelial cells and receive better visual recovery as well.

Financial Disclosure:

... gains financially from competing product or procedure, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... is employed by a competing company, ... has significant investment interest in a company producing, developing or supplying product or procedure presented